The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

A new study explores PET-guided risk stratification to tailor salvage therapy in pediatric relapsed/refractory Hodgkin ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...